Enliven Therapeutics, Inc. (ELVN) Insider Trading
Over the last 3 months, ELVN insiders made 0 open-market buys and 11 sales, a net sale of -$3.5M (SEC Form 4). Over the last 6 months, 121 institutions increased and 76 reduced their position (13F).
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
11
Net (3m)
-$3.5M
Insider trades by month Buys Sells
Dec
Jan
Feb
Mar
Apr
May
Context3-month price +21.2%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 20, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 1,302 | $40.25 |
| May 20, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 223 | $41.21 |
| May 20, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 3,475 | $39.53 |
| May 20, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Option | 5,000 | $2.48 |
| Apr 21, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 2,441 | $48.06 |
| Apr 21, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 2,419 | $47.39 |
| Apr 21, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 140 | $45.81 |
| Apr 21, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Option | 5,000 | $2.48 |
| Mar 27, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Option | 40,000 | $2.48 |
| Mar 27, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 40,000 | $35.10 |
| Mar 19, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 5,000 | $27.76 |
| Mar 19, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Option | 5,000 | $2.48 |
| Mar 11, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 10,129 | $30.19 |
| Mar 11, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Option | 10,129 | $2.48 |
| Mar 11, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 29,871 | $30.02 |
| Mar 11, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Option | 29,871 | $2.48 |
| Mar 10, 2026 | Hohl Benjaminofficer: CHIEF FINANCIAL OFFICER | Sell | 10,000 | $29.58 |
| Feb 19, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 45,000 | $26.17 |
| Feb 19, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Option | 45,000 | $2.48 |
| Feb 19, 2026 | Heyman Richard A.director | Sell | 1,230 | $26.18 |
| Feb 17, 2026 | Lyssikatos Joseph Pofficer: CHIEF SCIENTIFIC OFFICER | Grant | 18,750 | — |
| Feb 17, 2026 | Derynck Mika Kdirector | Grant | 17,126 | $27.16 |
| Feb 17, 2026 | Bauer Jakedirector | Grant | 17,126 | $27.16 |
| Feb 17, 2026 | Ballal Rahul D.director | Grant | 17,126 | $27.16 |
| Feb 17, 2026 | Patel Anishofficer: CHIEF OPERATING OFFICER | Grant | 120,000 | $27.16 |
| Feb 17, 2026 | Patel Anishofficer: CHIEF OPERATING OFFICER | Grant | 20,000 | — |
| Feb 17, 2026 | Lyssikatos Joseph Pofficer: CHIEF SCIENTIFIC OFFICER | Grant | 112,500 | $27.16 |
| Feb 17, 2026 | Hohl Benjaminofficer: CHIEF FINANCIAL OFFICER | Grant | 150,000 | $27.16 |
| Feb 17, 2026 | Hohl Benjaminofficer: CHIEF FINANCIAL OFFICER | Grant | 25,000 | — |
| Feb 17, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Grant | 150,000 | $27.16 |
Source: ELVN SEC Form 4 filings, latest May 20, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their ELVN positions over the last 6 months (SEC Form 13F).
Increased
121
New positions
77
Reduced
76
Sold out
45
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| ORBIMED ADVISORS LLC | Unchanged | 8.0M | Feb 17, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 8.0M | May 15, 2026 |
| FMR LLC | Reduced | 7.1M | Feb 17, 2026 |
| FMR LLC | Reduced | 6.8M | May 15, 2026 |
| POLAR CAPITAL HOLDINGS PLC | Increased | 5.1M | May 15, 2026 |
| COMMODORE CAPITAL LP | Unchanged | 4.7M | Feb 17, 2026 |
| VESTAL POINT CAPITAL, LP | Increased | 3.8M | Feb 17, 2026 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Unchanged | 3.7M | Feb 17, 2026 |
| BLACKROCK, INC. | Increased | 3.7M | May 13, 2026 |
| BLACKROCK, INC. | Increased | 3.6M | Feb 12, 2026 |
| POLAR CAPITAL HOLDINGS PLC | Increased | 3.5M | Feb 17, 2026 |
| COMMODORE CAPITAL LP | Reduced | 3.3M | May 15, 2026 |
| VESTAL POINT CAPITAL, LP | Reduced | 3.3M | May 15, 2026 |
| VR ADVISER, LLC | Unchanged | 3.2M | Feb 17, 2026 |
| VANGUARD GROUP INC | Increased | 2.8M | Jan 29, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.